Alerts will be sent to your verified email
Verify EmailGUFICBIO
Gufic Biosciences
|
Unichem Lab
|
Orchid Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
1.28 % | 5.35 % | n/a |
Financials
|
|||
5 yr Average ROE
|
25.05 % | -0.79 % | 0.86 % |
5yr average Equity Multiplier
|
2.22 | 1.32 | 1.61 |
5yr Average Asset Turnover Ratio
|
1.05 | 0.47 | 0.5 |
5yr Avg Net Profit Margin
|
10.9 % | -1.68 % | 0.56 % |
Price to Book
|
6.16 | 1.44 | 3.16 |
P/E
|
59.89 | 27.06 | 46.93 |
5yr Avg Cash Conversion Cycle
|
26.94 Days | 88.84 Days | 52.03 Days |
Inventory Days
|
66.86 Days | 151.32 Days | 112.47 Days |
Days Receivable
|
128.09 Days | 122.86 Days | 86.58 Days |
Days Payable
|
163.91 Days | 205.05 Days | 159.29 Days |
5yr Average Interest Coverage Ratio
|
13.1 | 2.41 | 3.01 |
5yr Avg ROCE
|
27.25 % | 1.04 % | 3.08 % |
5yr Avg Operating Profit Margin
|
18.45 % | 5.43 % | 11.84 % |
5 yr average Debt to Equity
|
0.51 | 0.11 | 0.37 |
5yr CAGR Net Profit
|
14.26 % | 32.0 % | n/a |
5yr Average Return on Assets
|
11.52 % | -0.65 % | 1.2 % |
Shareholdings
|
|||
Promoter Holding
|
72.52 % | 70.22 % | 69.84 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-2.48 % | 19.29 % | -20.12 % |
Change in Mutual Fund Holding (3 Yrs)
|
2.35 % | 1.31 % | 16.13 % |
Gufic Biosciences
|
Unichem Lab
|
Orchid Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|